Table 2.
Summary of measurements obtained by CMR and PET in placebo compared to ranolazine.
| Placebo | Ranolazine | P Value | |||||
|---|---|---|---|---|---|---|---|
| Baseline Mean (SD) | End-treatment Mean (SD) | Change from baseline (SE) | Baseline Mean (SD) | End-treatment Mean (SD) | Change from baseline (SE) | ||
| RV | |||||||
| EF (%) | 23.4 (9.8) | 22.5 (8.2) | −4.0 (2.2) | 34.1 (4.9) | 39.6 (5.1) | 7.6 (1.7) | 0.005 |
| EDV (ml) | 343.51 (73.0) | 327.3 (68.2) | 14.3 (19.0) | 244. 9 (46.2) | 246.2 (42.8) | −19.1 (14.2) | 0.266 |
| EDVi (ml /m2) | 186.9 (38.3) | 171.6 (53.6) | −21.3 (15.1) | 125.7 (33.1) | 129.9 (36.5) | 8.2 (11.1) | 0.226 |
| ESV (ml) | 266.9 (76.3) | 257.8 (77.5) | 17.8 (19.8) | 162.5 (38.9) | 149.2 (31.1 | −31.2 (14.7) | 0.128 |
| ESVi (ml /m2) | 145.9 (43. 7) | 135.5 (53.8) | −10.0 (13.8) | 82.7 (21.8) | 78.3 (21.9) | −4.8 (10.2) | 0.806 |
| SV (ml) | 76.6 (19.7) | 69.4 (13.8) | −8.3 (4.8) | 82.4 (13.4) | 97.0 (17.7) | 15.3 (3.9) | 0.004 |
| RV KE work density (mJ/ml) | 55.3 (45.6) | 43.8 (32.09) | 20.8 (20.7) | 6.6 (42.9) | 45.7 (34.5) | 20.5 (28.1) | 0.64 |
| PA energy loss (mW) | 9.2 (6.0) | 11.0 (6.8) | 0.8 (2.9) | 7.7 (3/4) | 6.7 (2.5) | −1.0 (0.96) | 0.46 |
| Flow (ml/min/g) | 1.5 (0.6) | 2.3 (2.8) | 0.77 (2.5) | 1.2 (0.47) | 1.2 (0.4) | 0.09 (0.6) | 0.95 |
| MVO2 (Kmono) (1/min) | 0.06 (0.01) | 0.06 (0.02) | 0.02 (0.02) | 0.06 (0.009) | 0.06 (0.01) | 0.10 (0.03) | 0.39 |
| MVO2 (ml/min/g) | 11.6 (2.3) | 13.8 (3.2) | 3.4 (4.7) | 11.9 (1.8) | 11.4 (2.8) | 1.9 (5.0) | 0.39 |
| SUVmean | 6.6 (3.5) | 5.9 (2.6) | −1.6 (3.2) | 6.1 (2.9) | 4.5 (3.0) | −2.5 (3.9) | 0.95 |
| SUVmax | 10.1 (6.1) | 9.3 (4.6) | −2.3 (5.4) | 10.02 (5.6) | 7.5 (4.9) | −4.3 (7.9) | 0.84 |
| LV | |||||||
| EF (%) | 54.6 (2.9) | 55.8 (6.0) | 0.9 (1.4) | 52.7 (10.1) | 56.7 (10.2) | 4.3 (1.1) | 0.095 |
| EDV (ml) | 136.4 (22.9) | 131.4 (7.3) | −6.5 (8.7) | 157.7 (41.0) | 172.4 (48.8) | 15.8 (7.0) | 0.081 |
| EDVi (ml /m2) | 73.4 (5.2) | 69.3 (16.6) | −5.0 (4.4) | 79.4 (17.5) | 88.9 (21.3) | 10.1 (3.5) | 0.025 |
| ESV (ml) | 61.8 (10.3) | 57.8 (5.9) | −4.2 (5.1) | 77.9 (38.4) | 77.7 (41.8) | −0.02 (4.1) | 0.544 |
| ESVi (ml /m2) | 33.3 (1.4) | 30.6 (8.9) | −3.0 (2.7 | 38.1 (13.5) | 38.9 (14.8) | 1.0 (2.2) | 0.276 |
| SV (ml) | 74.6 (14.2) | 73.5 (11.6) | −2.7 (4.1) | 79.8 (10.6) | 94.4 (12.9) | 15.6 (3.4) | 0.007 |
| Flow (ml/min/g) | 1.6 (0.5) | 1.7 (0.6) | 0.19 (0.8) | 1.4 (0.5) | 1.5 (0.4) | 0.20 (0.3) | 0.84 |
| MVO2 (Kmono) (1/min) | 0.07 (0.01) | 0.07 (0.02) | 0.02 (0.03) | 0.07 (0.01) | 0.07 (0.02) | 0.01 (0.03) | 0.55 |
| MVO2 (ml/min/g) | 13.1 (2.4) | 15.1 (3.1) | 3.5 (5.3) | 14.2 (2.2) | 13.1 (3.1) | 2.2 (6.3) | 0.55 |
| SUVmean | 9.5 (4.2) | 8.3 (2.5) | −0.23 (4.5) | 8.7 (3.0) | 7.9 (5.1) | −1.5 (5.8) | 0.64 |
| SUVmax | 14.6 (7.3) | 12.6 (4.2) | −3.6 (7.9) | 14.1 (5.8) | 12.2 (8.2) | −3.7 (11.3) | 0.95 |
| RV/LV SUVmean ratio | 0.68 (0.19) | 0.69 (0.18) | 0.007 (0.12) | 0.67 (0.20) | 0.56 (0.15) | −0.17 (0.14) | 0.05 |
| RV/LV SUVmax ratio | 0.68 (0.21) | 0.71 (0.24) | 0.02 (0.14) | 0.68 (0.22) | 0.59 (0.17) | −0.12 (0.19) | 0.46 |
LVEDV, left ventricular end-diastolic volume; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVESVi, left ventricular end-systolic volume index; RVEDV, right ventricular end-diastolic volume; RVEDVi, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume; RVESVi, right ventricular end-systolic volume index; SUV, standard uptake value.
Values listed in bold indicate statistical significance.